Top Markets
#1 OpenVPP OpenVPP +13,448.23%
#2 BugsCoin BugsCoin +49.61%
#3 GENIUS AI GENIUS AI +48.16%
#4 TAC TAC +34.76%
#5 Solidus Ai Tech Solidus Ai Tech +30.89%
#6 Zerebro Zerebro +28.49%
#7 Avici Avici +24.70%
#8 Swarms Swarms +19.08%
#9 Resolv RLP Resolv RLP +17.22%
#10 AI Rig Complex AI Rig Complex +12.79%
Coin of the day
OpenVPP OpenVPP
Settings
Language
ENGLISH
Currency
USD
Theme
Hikal Limited Hikal Limited

Hikal Limited

HIKAL
Rank in Stocks #10836
Hikal Limited, together with its subsidiaries, manufactures and sells various... Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal healthcare, biotech, crop protection, and specialty chemicals companies. It operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides. The company collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and APIs. It also provides specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Share Price
$2.09
Market Cap
$257.37M
Change (1 day)
0.76%
Change (1 year)
-55.56%
Country
IN
Trade Hikal Limited (HIKAL)

Category

Healthcare
P/E ratio for Hikal Limited (HIKAL)
P/E ratio as of April 2026 TTM: -177.28
According to Hikal Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -177.28. At the end of 2024 the company had a P/E ratio of 48.85.
P/E ratio history for Hikal Limited from 2005 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -177.28 -425.22%
2025 54.51 11.60%
2024 48.85 10.25%
2023 44.31 43.36%
2022 30.91 132.48%
2021 13.29 30.71%
2020 10.17 -53.22%
2019 21.74 -0.82%
2018 21.92 -15.52%
2017 25.95 10.83%
2016 23.41 -17.83%
2015 28.49 135.54%
2014 12.10 -54.57%
2013 26.63 174.40%
2012 9.70 -24.11%
2011 12.79 5.56%
2010 12.11 99.32%
2009 6.08 -53.66%
2008 13.12 -54.12%
2007 28.58 5.50%
2006 27.09 71.14%
2005 15.83 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPSEY.US
 30.58 -117.25%
FR
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MKGAF.US
 19.43 -110.96%
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
TAK.US
 79.16 -144.65%
JP
Zoetis Inc. Zoetis Inc.
Zoetis Inc.
ZTS.US
 19.85 -111.20%
US
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 36.75 -120.73%
IN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.